Get the Stockscreener App
7.8609
0.38%
0.0209
Neogenomics Inc stock is traded at $7.8609, with a volume of 152.55K.
It is up +0.38% in the last 24 hours and down -17.68% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$7.84
Open:
$7.85
24h Volume:
152.55K
Relative Volume:
0.08
Market Cap:
$1.01B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-12.68
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-2.24%
1M Performance:
-17.68%
6M Performance:
-47.67%
1Y Performance:
-47.50%
1-Day Range:
$7.73
$7.92
1-Week Range:
$7.4409
$8.69
52-Week Range:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.86 | 1.05B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
407.52 | 155.07B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.22 | 139.43B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
516.22 | 39.41B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.13 | 30.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
142.05 | 26.52B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics opposes US PTAB discretionary denial, citing public health concerns - MLex
Guggenheim Begins Coverage of NeoGenomics (NEO) with Neutral Stance | NEO Stock News - GuruFocus
Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating - marketscreener.com
NeoGenomics (NEO) Initiated with Neutral Rating by Guggenheim Analyst | NEO Stock News - GuruFocus
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook - Yahoo Finance
Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus
Chief Financial Officer of NeoGenomics Jeffrey Sherman Buys 14% More Shares - Yahoo Finance
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - SelectScience
Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus
Assessing NeoGenomics: Insights From 9 Financial Analysts - Benzinga
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 - GuruFocus
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 | NEO Stock News - GuruFocus
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - Investing.com
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - MarketBeat
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sand - GuruFocus
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sandler | NEO Stock News - GuruFocus
NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
How to Take Advantage of moves in (NEO) - news.stocktradersdaily.com
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript - MSN
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO S - GuruFocus
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO Stock News - GuruFocus
NeoGenomics Repays $201.3 Million Convertible Senior Notes - marketscreener.com
NeoGenomics price target lowered to $10 from $17 at Morgan Stanley - Yahoo Finance
NeoGenomics clears $201.25M convertible debt ahead of maturity By Investing.com - Investing.com India
NeoGenomics clears $201.25M convertible debt ahead of maturity - Investing.com
NeoGenomics Pays Off 1.25% Convertible Senior Notes - Yahoo Finance
NeoGenomics (NEO) Shares Drop After Disappointing Q1 Revenue Rep - GuruFocus
NeoGenomics targets 25% annual NGS growth with new product launches in 2025 - MSN
NeoGenomics (NEO) Stock Target Reduced by Morgan Stanley Amid Q1 - GuruFocus
Leerink Partners Downgrades NeoGenomics (BMV:NEO) - Nasdaq
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
NeoGenomics (NEO) Faces Price Target Cut Amid Significant Selloff | NEO Stock News - GuruFocus
NeoGenomics (NEO) Faces Price Target Reduction Amid Sales Challe - GuruFocus
NeoGenomics (NEO) Price Target Cut by BTIG Amid Revenue Concerns - GuruFocus
NeoGenomics stock hits 52-week low at $6.25 amid market challenges - Investing.com India
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade) (NEO) - Seeking Alpha
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform - BioSpace
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
NeoGenomics Reports Strong Q1 2025 Performance - TipRanks
NeoGenomics (NEO) Kicks Off 2025 with Strong Revenue Momentum | - GuruFocus
NeoGenomics: Q1 Earnings Snapshot - MySA
NeoGenomics Reports Strong Q1 2025 Earnings Growth - TipRanks
NeoGenomics Q1 2025 Earnings Call Transcript - MarketBeat
NeoGenomics (NEO) Downgraded Amid Growth Concerns | NEO Stock Ne - GuruFocus
Why NeoGenomics (NEO) Stock Is Nosediving - MSN
Fort Myers-based NeoGenomics posts $26M net loss in Q1 - Gulfshore Business
Earnings call transcript: NeoGenomics Q1 2025 revenue misses forecast, stock drops - Investing.com Nigeria
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics stock drops on Q1 miss (NEO:NASDAQ) - Seeking Alpha
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):